Phenytoin as a risk factor in gingival hyperplasia.
Fifty-four out-patients with epilepsy who had been taking phenytoin for more than one year were examined for gingival hyperplasia. Approximately 76% of patients showed either mild or no gingival hyperplasia. Lesion severity was then compared statistically to phenytoin dosage and drug concentrations as well as to other clinical and laboratory parameters. There was a tendency for gingival hypertrophy to be associated with both increasing dosage of phenytoin per unit of body weight and the duration of phenytoin administration. All patients followed had a statistically significant progressive trend to increasing gingival hyperplasia with higher total and free phenytoin concentration.
Perlík
F
F
First Department of Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Kolínová
M
M
Zvárová
J
J
Patzelová
V
V
D000328:Adult; D000704:Analysis of Variance; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D016009:Chi-Square Distribution; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D005885:Gingival Hyperplasia / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D018570:Risk Assessment; D012307:Risk Factors
D000927:Anticonvulsants; D010672:Phenytoin